Using the anti-CD40 monoclonal antibody FGK4.5 [61] in combination with celecoxib, a COX-2 inhibitor, Kosaka et al. reported significant survival benefits in the murine Gl261 tumor model [182]. This evidence concerns the gene CD40 and neoplasm.